T. Rowe Price Associates’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $706K | Buy |
75,404
+9,290
| +14% | +$87K | ﹤0.01% | 2137 |
|
|
2025
Q1 | $813K | Buy |
66,114
+9,095
| +16% | +$112K | ﹤0.01% | 2054 |
|
|
2024
Q4 | $754K | Buy |
57,019
+8,092
| +17% | +$107K | ﹤0.01% | 2089 |
|
|
2024
Q3 | $942K | Buy |
48,927
+729
| +2% | +$14K | ﹤0.01% | 1996 |
|
|
2024
Q2 | $990K | Buy |
48,198
+3,688
| +8% | +$75.8K | ﹤0.01% | 1899 |
|
|
2024
Q1 | $1.06M | Buy |
44,510
+18,243
| +69% | +$434K | ﹤0.01% | 1891 |
|
|
2023
Q4 | $568K | Buy |
26,267
+1,857
| +8% | +$40.2K | ﹤0.01% | 2121 |
|
|
2023
Q3 | $355K | Buy |
24,410
+1,471
| +6% | +$21.4K | ﹤0.01% | 2269 |
|
|
2023
Q2 | $481K | Buy |
22,939
+11,575
| +102% | +$243K | ﹤0.01% | 2147 |
|
|
2023
Q1 | $241K | Buy |
11,364
+2,000
| +21% | +$42.4K | ﹤0.01% | 2444 |
|
|
2022
Q4 | $238K | Buy |
9,364
+935
| +11% | +$23.8K | ﹤0.01% | 2463 |
|
|
2022
Q3 | $203K | Buy |
+8,429
| New | +$203K | ﹤0.01% | 2535 |
|
|
2021
Q4 | – | Sell |
-516,098
| Closed | -$9.86M | – | 3031 |
|
|
2021
Q3 | $9.86M | Buy |
516,098
+95,678
| +23% | +$1.83M | ﹤0.01% | 1419 |
|
|
2021
Q2 | $7.22M | Sell |
420,420
-18,597
| -4% | -$319K | ﹤0.01% | 1454 |
|
|
2021
Q1 | $9.82M | Buy |
439,017
+267,578
| +156% | +$5.98M | ﹤0.01% | 1395 |
|
|
2020
Q4 | $3.81M | Buy |
+171,439
| New | +$3.81M | ﹤0.01% | 1477 |
|